S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

MediPharm Labs Stock Price, Forecast & Analysis (OTCMKTS:MEDIF)

$3.04
-0.01 (-0.33 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$3.01
Now: $3.04
$3.14
50-Day Range
$2.72
MA: $3.30
$4.02
52-Week Range
$0.91
Now: $3.04
$5.65
Volume323,477 shs
Average Volume274,178 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MediPharm Labs Corp., together with its subsidiaries, produces and sells pharma-grade cannabis oil and concentrates for derivative products in Canada and Australia. It also provides cannabis contract processing services to licensed producers and growers; and tolling services to Canadian licensed cultivators of cannabis for selling cannabis oil, formulations, and derivatives under their own brand. In addition, the company supplies purified cannabis concentrate raw materials and product formulations for ready-to-sell advanced cannabis products. Further, it engages in the real estate business. The company was founded in 2015 and is headquartered in Barrie, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MEDIF
CUSIPN/A
CIKN/A
Phone705-719-7425

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees56
Next Earnings DateN/A
OptionableNot Optionable

Receive MEDIF News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDIF and its competitors with MarketBeat's FREE daily newsletter.


MediPharm Labs (OTCMKTS:MEDIF) Frequently Asked Questions

What is MediPharm Labs' stock symbol?

MediPharm Labs trades on the OTCMKTS under the ticker symbol "MEDIF."

What price target have analysts set for MEDIF?

1 brokers have issued 1-year price targets for MediPharm Labs' shares. Their forecasts range from $8.50 to $8.50. On average, they anticipate MediPharm Labs' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 179.6% from the stock's current price. View Analyst Price Targets for MediPharm Labs.

What is the consensus analysts' recommendation for MediPharm Labs?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediPharm Labs in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediPharm Labs.

Has MediPharm Labs been receiving favorable news coverage?

Headlines about MEDIF stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MediPharm Labs earned a daily sentiment score of -3.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for MediPharm Labs.

Who are some of MediPharm Labs' key competitors?

What other stocks do shareholders of MediPharm Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediPharm Labs investors own include Canopy Growth (CGC), Charlotte's Web (CWBHF), Baozun (BZUN), Aurora Cannabis (ACB), Baidu (BIDU), KushCo (KSHB), OrganiGram (OGI), Zynerba Pharmaceuticals (ZYNE), Innovative Industrial Properties (IIPR) and Supreme Cannabis (SPRWF).

Who are MediPharm Labs' key executives?

MediPharm Labs' management team includes the folowing people:
  • Mr. Patrick McCutcheon, Founder, CEO & Chairman
  • Mr. Keith Strachan, Co-Founder, Pres & Director
  • Mr. Christopher J. Hobbs C.A., CA, CFO & Director (Age 53)
  • Ms. Sybil Taylor, Chief Marketing Officer
  • Mr. Kirk Binns, Exec. VP of Global Accounts

How do I buy shares of MediPharm Labs?

Shares of MEDIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MediPharm Labs' stock price today?

One share of MEDIF stock can currently be purchased for approximately $3.04.

What is MediPharm Labs' official website?

The official website for MediPharm Labs is http://www.medipharmlabs.com/.

How can I contact MediPharm Labs?

The company can be reached via phone at 705-719-7425.


MarketBeat Community Rating for MediPharm Labs (OTCMKTS MEDIF)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  7
MarketBeat's community ratings are surveys of what our community members think about MediPharm Labs and other stocks. Vote "Outperform" if you believe MEDIF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDIF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel